Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566305 | 0.91 | PARP1 (0.49) | PARP1ARTSHRCYP3A4CYP2C9 | |
| SCHEMBL24390020 | 0.90 | PARP1 (0.51) | PARP1ARTSHRCYP3A4CYP2C9 | |
| SCHEMBL25890293 | 0.90 | PARP1 (0.49) | PARP1ARTSHRCYP3A4CYP2C9 | |
| SCHEMBL25313203 | 0.90 | PARP1 (0.49) | PARP1ARTSHRCYP3A4CYP2C9 | |
| SCHEMBL29565633 | 0.90 | PARP1 (0.51) | PARP1ARTSHRCYP3A4CYP2C9 | |
| SCHEMBL29565753 | 0.86 | PARP1 (0.45) | PARP1ARTSHRCYP3A4CYP2C9 | |
| SCHEMBL30132749 | 0.82 | PARP1 (0.70) | PARP1TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25890319 | 0.82 | PARP1 (0.70) | PARP1TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25315687 | 0.82 | PARP1 (0.45) | PARP1TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25890832 | 0.82 | PARP1 (0.41) | PARP1ARTSHRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885AR 3446/4885TSHR 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.